Pioneering Novel Therapeutics for Gastrointestinal Disorders
We are a clinical-stage pharmaceutical company based in the San Francisco Bay Area, dedicated to developing first-in-class dimer conjugates with superior therapeutic profiles. Our mission is to address critical unmet needs in functional gastrointestinal disorders by targeting the underlying mechanisms of visceral hypersensitivity and hypermotility.
Proprietary Dimer Platform Technology
At the core of our innovation is a proprietary dimer platform technology that enables the creation of novel molecules designed for enhanced efficacy and safety. This unique approach allows us to develop therapies that go beyond symptom management to address the physiological drivers of complex GI conditions. Our lead program focuses on delivering meaningful relief for patients suffering from irritable bowel syndrome with diarrhea, a condition that significantly impacts quality of life.
Intellectual Property and Scientific Rigor
Our pipeline is protected by composition of matter and method of use patents, reflecting the novelty and defensibility of our science. We are committed to rigorous clinical development and evidence-based advancement of our candidates, ensuring that every step we take is grounded in sound biology and patient-centered outcomes.
A Commitment to Innovation
As a clinical-stage organization, we operate at the intersection of discovery and translation. Our team brings together expertise in chemistry, pharmacology, and clinical development to advance therapies that have the potential to redefine treatment standards. We are driven by the belief that patients deserve better options and that innovative science can deliver them.